ALD Clinical Trials

123 recruitingLast updated: July 25, 2026

There are 123 actively recruiting ald clinical trials across 40 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4. Top locations include Boston, Massachusetts, United States, Chongqing, Chongqing Municipality, China, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


ALD Trials at a Glance

123 actively recruiting trials for ald are listed on ClinicalTrialsFinder across 6 cities in 40 countries. The largest study group is Not Applicable with 29 trials, with the heaviest enrollment activity in Boston, Chongqing, and Beijing. Lead sponsors running ald studies include Qifu Li, Centre Hospitalier Universitaire, Amiens, and Peking Union Medical College Hospital.

Browse ald trials by phase

Treatments under study

About ALD Clinical Trials

Looking for clinical trials for ALD? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ALD trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ALD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 123 trials

Recruiting
Phase 2

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled127 locationsNCT05006716
Recruiting

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

SYNGAP1-Related Intellectual DisabilityDLG4FOXP1+184 more
Simons Searchlight100,000 enrolled2 locationsNCT01238250
Recruiting

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Mantle Cell LymphomaSudden Cardiac DeathChronic Lymphocytic Leukemia (CLL)+3 more
National Heart, Lung, and Blood Institute (NHLBI)135 enrolled1 locationNCT05724121
Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma+2 more
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00923507
Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Heart FailurePainInsomnia+22 more
Duke University5,000 enrolled51 locationsNCT04278404
Recruiting
Phase 2

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled136 locationsNCT04840602
Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Follicular Lymphoma ( FL)+3 more
iOMEDICO AG2,950 enrolled1 locationNCT06043011
Recruiting
Phase 1

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Lymphoma, Non-HodgkinB-cell LymphomaWaldenstrom Macroglobulinemia+4 more
Eli Lilly and Company215 enrolled50 locationsNCT07101328
Recruiting

Study on the Application of Liquid Chromatography-Tandem Mass Spectrometry for the Determination of Aldosterone and Renin Activity in the Diagnosis of Primary Aldosteronism by Captopril Test

Primary Aldosteronism
Peking Union Medical College Hospital800 enrolled1 locationNCT07691801
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

Primary Hyperaldosteronism
AstraZeneca250 enrolled89 locationsNCT07007793
Recruiting
Not Applicable

Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism

Primary AldosteronismEndocrine Hypertension
Bangladesh Medical University104 enrolled1 locationNCT07688928
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Not Applicable

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Chronic Lymphocytic LeukemiaLymphomaFollicular Lymphoma+6 more
UNC Lineberger Comprehensive Cancer Center40 enrolled1 locationNCT06860880
Recruiting
Not Applicable

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients

Liver FibrosisNon-alcoholic Fatty Liver Disease NAFLDAlcoholic Liver Disease (ALD)
University Hospital, Angers1,788 enrolled13 locationsNCT05699018
Recruiting
Phase 2

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

HypercortisolismHyperaldosteronismCushing s Syndrome
National Cancer Institute (NCI)80 enrolled1 locationNCT06246357
Recruiting
Phase 2

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center40 enrolled9 locationsNCT07231952
Recruiting

Diagnosing Variable Primary Aldosteronism.

Primary AldosteronismHigh Blood Pressure
Queen Mary University of London100 enrolled1 locationNCT05765786
Recruiting
Not Applicable

Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension

AdrenalectomyPrimary Aldosteronism Due to Conn AdenomaRadiofrequency Ablation Treatment
University Hospital, Toulouse134 enrolled1 locationNCT07470580